In this subgroup analysis, even patients with IDH1/2 mutation (Group B), previously known as a better prognostic factor for glioma, had shorter PFS and OS than patients with the IDH1/2 wildtype if accompanied by CDKN2A deletion (Group C). This evidence concerns the gene IDH1 and central nervous system cancer.